Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | SGK1 | O00141 | 5/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 6/20 | 0.38 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962013 | 1.00 | MAPK1 (0.46) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL22011278 | 1.00 | MAPK1 (0.46) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL21961967 | 0.87 | MAPK1 (0.50) | MAPK1GSK3B | |
| SCHEMBL21962015 | 0.87 | MAPK1 (0.50) | MAPK1GSK3B | |
| SCHEMBL21961966 | 0.87 | MAPK1 (0.50) | MAPK1GSK3B | |
| SCHEMBL24179613 | 0.85 | MAPK1 (0.41) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL21961965 | 0.85 | MAPK1 (0.40) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL22011265 | 0.85 | MAPK1 (0.40) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL22011263 | 0.84 | MAPK1 (0.47) | MAPK1SGK1GSK3BCAMKK2LIMK2 | |
| SCHEMBL21961980 | 0.84 | MAPK1 (0.47) | MAPK1SGK1GSK3BCAMKK2LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428416-B2 | ERK inhibitors and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| EP-3880677-A1 | ERK INHIBITORS AND USES THEREOF | California Institute of Technology (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102686-A1 | ERK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | MAPK1 11/4885SGK1 131/4885GSK3B 358/4885 |
| US-12428416-B2 | ERK inhibitors and uses thereof | MAPKAPK2, MAPK3, MAP4K2 | MAPK1 11/4885SGK1 131/4885GSK3B 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.